how safe is glp-1 Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity FAQ of the Month: Is
Description
Notably, when an acylated GCGR agonist was administered alone, it led to approximately 20% weight loss in mice on a high-fat diet, and this weight loss was further enhanced when the GCGR agonist was combined with a GLP-1R/GIPR co-agonist
Will I gain weight again after stopping GLP-1
Semaglutide and tirzepatide clinical trials included significant numbers of postmenopausal women with acceptable safety profiles
They track the intended effects (improved A1C, better lipids) alongside safety markers (kidney function, pancreatic enzymes)
It's the reality of the world we live in now
In other words, it may make eating feel slightly less rewarding, which can help reduce the desire for food and emotional eating
